116 related articles for article (PubMed ID: 16933266)
1. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Nichol JL
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
[TBL] [Abstract][Full Text] [Related]
2. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.
Newland A; Caulier MT; Kappers-Klunne M; Schipperus MR; Lefrere F; Zwaginga JJ; Christal J; Chen CF; Nichol JL
Br J Haematol; 2006 Nov; 135(4):547-53. PubMed ID: 17061981
[TBL] [Abstract][Full Text] [Related]
3. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.
Bussel JB; Kuter DJ; George JN; McMillan R; Aledort LM; Conklin GT; Lichtin AE; Lyons RM; Nieva J; Wasser JS; Wiznitzer I; Kelly R; Chen CF; Nichol JL
N Engl J Med; 2006 Oct; 355(16):1672-81. PubMed ID: 17050891
[TBL] [Abstract][Full Text] [Related]
4. Platelet production bolstered with romiplostim approval.
Morrow T
Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
[No Abstract] [Full Text] [Related]
5. Immune thrombocytopenic purpura--the changing therapeutic landscape.
Bromberg ME
N Engl J Med; 2006 Oct; 355(16):1643-5. PubMed ID: 17050888
[No Abstract] [Full Text] [Related]
6. FDA approves thrombopoiesis-stimulating agent.
Thompson CA
Am J Health Syst Pharm; 2008 Oct; 65(19):1788. PubMed ID: 18796411
[No Abstract] [Full Text] [Related]
7. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
Chouhan JD; Herrington JD
Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
[TBL] [Abstract][Full Text] [Related]
8. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
9. Romiplostim: a second-generation thrombopoietin agonist.
Cohn CS; Bussel JB
Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim: a novel thrombopoiesis-stimulating agent.
Perreault S; Burzynski J
Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
[TBL] [Abstract][Full Text] [Related]
11. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
Tiu RV; Sekeres MA
Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
[TBL] [Abstract][Full Text] [Related]
12. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
Godeau B;
Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
[No Abstract] [Full Text] [Related]
13. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
Nurden AT; Viallard JF; Nurden P
Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
[TBL] [Abstract][Full Text] [Related]
14. Drug evaluation: AMG-531 for the treatment of thrombocytopenias.
Rice L
Curr Opin Investig Drugs; 2006 Sep; 7(9):834-41. PubMed ID: 17002262
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study.
Kumagai Y; Fujita T; Ozaki M; Sahashi K; Ohkura M; Ohtsu T; Arai Y; Sonehara Y; Nichol JL
J Clin Pharmacol; 2007 Dec; 47(12):1489-97. PubMed ID: 17925591
[TBL] [Abstract][Full Text] [Related]
16. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura.
Shirasugi Y; Ando K; Hashino S; Nagasawa T; Kurata Y; Kishimoto Y; Iwato K; Ohtsu T; Berger DP
Int J Hematol; 2009 Sep; 90(2):157-165. PubMed ID: 19543952
[TBL] [Abstract][Full Text] [Related]
17. Novel thrombopoietic agents: preliminary activity, potential benefit.
Bussel JB
J Support Oncol; 2007 Apr; 5(4 Suppl 2):63-84. PubMed ID: 17550056
[No Abstract] [Full Text] [Related]
18. New insights and therapeutics for immune-mediated thrombocytopenia.
Metjian A; Abrams CS
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
[TBL] [Abstract][Full Text] [Related]
19. Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S26-32. PubMed ID: 19245931
[TBL] [Abstract][Full Text] [Related]
20. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.
Yang BB; Doshi S; Arkam K; Franklin J; Chow AT
Clin Pharmacokinet; 2016 Sep; 55(9):1045-58. PubMed ID: 27056734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
